MX2018006674A - Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control. - Google Patents

Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.

Info

Publication number
MX2018006674A
MX2018006674A MX2018006674A MX2018006674A MX2018006674A MX 2018006674 A MX2018006674 A MX 2018006674A MX 2018006674 A MX2018006674 A MX 2018006674A MX 2018006674 A MX2018006674 A MX 2018006674A MX 2018006674 A MX2018006674 A MX 2018006674A
Authority
MX
Mexico
Prior art keywords
fucose
deoxy
fluoro
combination
checkpoint inhibitor
Prior art date
Application number
MX2018006674A
Other languages
English (en)
Inventor
Leung Law Che-
Gardai Shyra
Senter Peter
Okeley Nicole
Field Jessica
Original Assignee
Seattle Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Genetics Inc filed Critical Seattle Genetics Inc
Publication of MX2018006674A publication Critical patent/MX2018006674A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

La presente invención se dirige a métodos para tratar cáncer que comprende administrar a un sujeto que lo necesita una cantidad efectiva de 2-desoxi-2-fluoro-L-fucosa o un profármaco del mismo, o una de sus sales farmacéuticamente aceptables, en combinación co 5 n un inhibidor del punto de control.
MX2018006674A 2015-12-04 2016-12-02 Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control. MX2018006674A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562263228P 2015-12-04 2015-12-04
US201662308583P 2016-03-15 2016-03-15
US201662321857P 2016-04-13 2016-04-13
PCT/US2016/064783 WO2017096274A1 (en) 2015-12-04 2016-12-02 Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor

Publications (1)

Publication Number Publication Date
MX2018006674A true MX2018006674A (es) 2018-11-09

Family

ID=58797961

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018006674A MX2018006674A (es) 2015-12-04 2016-12-02 Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.

Country Status (13)

Country Link
US (1) US20180353524A1 (es)
EP (1) EP3383404A4 (es)
JP (1) JP6906520B2 (es)
KR (1) KR20180086233A (es)
CN (1) CN108289903B (es)
AU (1) AU2016362993A1 (es)
BR (1) BR112018011261A2 (es)
CA (1) CA3005997A1 (es)
EA (1) EA201891340A1 (es)
IL (1) IL259479B (es)
MX (1) MX2018006674A (es)
SG (2) SG11201804263PA (es)
WO (1) WO2017096274A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2711622T3 (es) 2010-08-05 2019-05-06 Seattle Genetics Inc Inhibición de la fucosilación in vivo usando análogos de fucosa
CA3037380A1 (en) 2016-10-11 2018-04-19 Agenus Inc. Anti-lag-3 antibodies and methods of use thereof
CN110740734A (zh) * 2017-06-07 2020-01-31 西雅图基因公司 具有降低的表面岩藻糖基化的t细胞及其制备和使用方法
US11911404B2 (en) * 2017-10-13 2024-02-27 H. Lee Moffitt Cancer Center And Research Institute, Inc. Fucosylation and immune surveillance in melanoma
MA53434A (fr) 2018-08-23 2021-12-01 Seagen Inc Anticorps anti-tigit
CA3123591A1 (en) * 2018-12-19 2020-06-25 Seagen Inc. Controlled fucosylation of antibodies
US20220305038A1 (en) * 2019-08-16 2022-09-29 H. Lee Moffitt Cancer Center And Research Institute, Inc. Fucosylation and immune modulation in cancer
CN111973749B (zh) * 2020-09-07 2023-03-21 威海人生药业集团股份有限公司 一种抗肿瘤免疫治疗的药物组合物
WO2022221766A1 (en) * 2021-04-16 2022-10-20 H. Lee Moffitt Cancer Center And Research Institute, Inc. Fucosylation and immune modulation in cancer
CN113274502B (zh) * 2021-05-05 2023-01-03 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 用于特定型三阴乳腺癌免疫治疗的组合物
WO2022236017A1 (en) * 2021-05-06 2022-11-10 H. Lee Moffitt Cancer Center And Research Institute, Inc. L-fucose and anti-androgen receptor therapy for treatment of cancer
CN113413465B (zh) * 2021-06-15 2022-06-03 北京大学 岩藻糖基化抑制剂在抗癌导致炎症中的应用
CN115466297B (zh) * 2022-08-25 2023-07-07 青岛农业大学 L-岩藻糖的应用以及动物饲料

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2711622T3 (es) 2010-08-05 2019-05-06 Seattle Genetics Inc Inhibición de la fucosilación in vivo usando análogos de fucosa
EA201690912A1 (ru) * 2013-11-05 2016-10-31 Когнейт Биосервисис, Инк. Комбинации ингибиторов контрольных точек и терапевтических средств для лечения рака

Also Published As

Publication number Publication date
EP3383404A1 (en) 2018-10-10
IL259479A (en) 2018-07-31
SG10202005298RA (en) 2020-07-29
KR20180086233A (ko) 2018-07-30
JP6906520B2 (ja) 2021-07-21
SG11201804263PA (en) 2018-06-28
IL259479B (en) 2022-03-01
CN108289903A (zh) 2018-07-17
BR112018011261A2 (pt) 2018-11-21
EA201891340A1 (ru) 2018-11-30
CA3005997A1 (en) 2017-06-08
US20180353524A1 (en) 2018-12-13
WO2017096274A1 (en) 2017-06-08
AU2016362993A1 (en) 2018-07-12
EP3383404A4 (en) 2019-07-31
CN108289903B (zh) 2021-08-03
JP2019501145A (ja) 2019-01-17

Similar Documents

Publication Publication Date Title
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
MX2021004881A (es) Combinacion de palbociclib y rad1901 para usarse en el tratamiento de cancer de mama en un sujeto con cancer positivo a receptor de estrogeno.
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
MX2018000396A (es) Compuestos aza sustituidos como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak-4).
MX2018016193A (es) Métodos para el tratamiento del cáncer de ovario.
MX2017004471A (es) Compuestos de triazolopiridina y métodos para el tratamiento de fibrosis cística.
MX2017001154A (es) Metodos y combinaciones terapeuticas para tratar tumores.
PH12015502075A1 (en) Treatment of cataplexy
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
EA201591509A1 (ru) Ингибиторы cdc7
PH12016500270A1 (en) Combination of a mek inhibitor and an erk inhibitor for use in treatment of hyperproliferative diseases
MX368286B (es) Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto de quinazolinona 5-sustituida para tratar cancer.
MX2015014599A (es) Terapia de combinacion que comprende un inhibidor de tor cinasa y un analogo de citidina para tracar cancer.
PH12016502352A1 (en) Pharmaceutical composition
PH12016502353A1 (en) Pharmaceutical composition
NZ722600A (en) Methods of treating mild brain injury
GEP20196984B (en) Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
MX2021014120A (es) Tratamiento de los sintomas asociados a terapia privacion de androgenos.
MX2018001684A (es) Metodo de curacion de heridas.
MX2018006631A (es) Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas.
MX2018004532A (es) Combinacion de trazodona y gabapentina para el tratamiento de dolor.
GB2546703A (en) Compounds
PH12014000105A1 (en) Therapeutic methods and compositions for treating diabetes utilizing diterpenoid compounds
IN2014DE00818A (es)